[1]白小慧,魏 英,李王斌,等.局部晚期直肠癌患者血清NOP53 mRNA，FNDC1 mRNA表达与临床病理特征及其对新辅助放化疗疗效评估价值研究[J].现代检验医学杂志,2025,40(04):55-60.[doi:10.3969/j.issn.1671-7414.2025.04.010]
　BAI Xiaohui,WEI Ying,LI Wangbin,et al.Study on the Expression and Clinical Pathological Characteristics of Serum NOP53 mRNA and FNDC1 mRNA in Patients with Locally Advanced Rectal Cancer and Their Value in Evaluating the Efficacy of Neoadjuvant Radiotherapy and Chemotherapy[J].Journal of Modern Laboratory Medicine,2025,40(04):55-60.[doi:10.3969/j.issn.1671-7414.2025.04.010]
点击复制

局部晚期直肠癌患者血清NOP53 mRNA，FNDC1 mRNA表达与临床病理特征及其对新辅助放化疗疗效评估价值研究()

《现代检验医学杂志》[ISSN:/CN:]

卷:
第40卷
期数:
2025年04期
页码:
55-60
栏目:
论著
出版日期:
2025-07-15

文章信息/Info

Title:
Study on the Expression and Clinical Pathological Characteristics of Serum NOP53 mRNA and FNDC1 mRNA in Patients with Locally Advanced Rectal Cancer and Their Value in Evaluating the Efficacy of Neoadjuvant Radiotherapy and Chemotherapy
文章编号:
1671-7414（2025）04-055-06
作者:
白小慧a，魏 英a，李王斌a，贺 宁b，李雨遥b，赵昌涛a
（西安交通大学第一附属医院榆林医院a. 肿瘤放疗科；b. 肿瘤内科，陕西榆林 719000）
Author(s):
BAI Xiaohuia, WEI Yinga, LI Wangbina, HE Ningb, LI Yuyaob, ZHAO Changtaoa
(a. Department of Tumor Radiotherapy; b. Department of Medical Oncology, Yulin Hospital, the First Affiliated Hospital of Xi’an Jiaotong University, Shaanxi Yulin 719000, China)
关键词:
直肠癌; 核糖体生物发生因子核仁蛋白53; Ⅲ型纤维连接蛋白域蛋白1; 新辅助放化疗
分类号:
R735.37；R730.43
DOI:
10.3969/j.issn.1671-7414.2025.04.010
文献标志码:
A
摘要:
目的 探讨局部晚期直肠癌患者血清核糖体生物发生因子核仁蛋白53（NOP53）mRNA 和Ⅲ型纤维连接蛋白域蛋白1(FNDC1) mRNA 对新辅助放化疗（NACRT）疗效的评估价值。方法 选取 2020 年1 月~ 2023 年1 月西安交通大学第一附属医院榆林医院诊治的140 例接受NACRT 治疗的局部晚期直肠癌患者为研究组，根据NACRT 治疗疗效，分为反应良好组(n=99) 与反应不良组(n=41)。选取同期70 例健康人为对照组。采用实时荧光定量PCR 检测两组血清NOP53 mRNA，FNDC1 mRNA 水平。Logistic 回归分析影响NACRT 治疗疗效的因素。受试者工作特征（ROC）曲线分析血清NOP53 mRNA，FNDC1 mRNA 对直肠癌NACRT 疗效的评估价值。结果 研究组血清NOP53 mRNA（3.21±0.36），FNDC1 mRNA（2.73±0.34）表达高于对照组（0.61±0.17，0.72±0.18），差异具有统计学意义（t=57.267，46.287，均P ＜ 0.001）。T 分期T4 期、N 分期N1+N2 直肠癌患者血清NOP53 mRNA（4.08±0.43，4.10±0.40），FNDC1mRNA（3.62±0.39，3.40±0.39）表达高于T 分期T3 期（2.52±0.30，2.02±0.29）、N 分期N0 患者（2.21±0.31，1.02±0.30），差异具有统计学意义（t=25.241 ～ 40.106，P 均＜ 0.001）。反应不良组T 分期T4 占比（73.17%）、N分期N1+N2 占比（75.61%）、血清NOP53 mRNA（5.56±0.39）、FNDC1 mRNA（4.42±0.38）高于反应良好组（32.32%，43.43%，2.24±0.31，2.03±0.29），差异具有统计学意义（t/χ2 =12.045 ～ 53.337，均P ＜ 0.001）。T 分期T4 期、N分期N1+N2，血清NOP53 mRNA 高表达和血清FNDC1 mRNA 高表达是影响直肠癌NACRT 疗效的危险因素（Waldχ2 =9.463~15.589，均P ＜ 0.001）。血清NOP53 mRNA，FNDC1 mRNA 联合对直肠癌NACRT 疗效评估的曲线下面积高于血清NOP53 mRNA，FNDC1 mRNA 单项预测，差异具有统计学意义(Z=4.645，4.321，均P ＜ 0.001)。结论 局部晚期直肠癌患者血清NOP53 mRNA，FNDC1 mRNA 水平升高，两者与患者不良临床病理特征有关, 联合血清NOP53mRNA，FNDC1 mRNA 能够有效预测直肠癌患者NACRT 治疗的临床疗效。
Abstract:
Objective To investigate the value of serum ribosomal biogenesis factor nucleolar protein53（NOP53） mRNA and fibronectin type III domain containing 1 (FNDC1） mRNA in evaluating the efficacy of neoadjuvant chemoradiotherapy (NACRT) in patients with locally advanced rectal cancer. Methods A total of 140 patients with locally advanced rectal cancer who received NACRT treatment in Yulin Hospital the First Affiliated Hospital of Xi’an Jiaotong University from January 2020 to January 2023 were selected as the study group. According to the efficacy of NACRT treatment, they were divided into good response group (99 cases) and poor response group (41 cases). At the same time, 70 healthy people were selected as control group.Real-time fluorescence quantitative PCR was used to detect serum NOP53 mRNA and FNDC1 mRNA levels in the two groups. Logistic regression analysis was used to analyze the factors affecting the efficacy of NACRT. The value of serum NOP53 mRNA and FNDC1 mRNA in evaluating the efficacy of NACRT for rectal cancer was analyzed by receiver operating characteristic analysis.Results The expression of serum NOP53 mRNA (3.21 ± 0.36) and FNDC1 mRNA (2.73 ± 0.34) in the study group was higher than that in the control group（0.61±0.17，0.72±0.18）, and the differences were statistically significant (t = 57.267,46.287, all P < 0.001）.The expression of serum NOP53 mRNA (4.08 ± 0.43,4.10 ± 0.40) and FNDC1 mRNA (3.62 ± 0.39,3.40 ± 0.39) in patients with T stage T4 and N stage N1 + N2 rectal cancer was higher than that in patients with T stage T3（2.52±0.30， 2.02±0.29）and N stage N0（2.21±0.31，1.02±0.30）, and the differences were statistically significant (t = 25.241~40.106, all P < 0.001）.The proportion of T stage T4（73.17%）, N stage N1 + N2（75.61%）, serum NOP53 mRNA (5.56 ± 0.39) and FNDC1 mRNA (4.42 ± 0.38) in the poor response group were higher than those in the good response group（32.32%， 43.43%，2.24±0.31，2.03±0.29）, and the differences were statistically significant (t= 12.045~53.337, all P < 0.001）.T stage T4, N stage N1 + N2, high serum NOP53 mRNA , high serum FNDC1 mRNA were risk factors affecting the efficacy of NACRT for rectal cancer (Wald χ2 =9.463~15.589, all P < 0.001）.The AUC of serum NOP53 mRNA combined with FNDC1 mRNA in evaluating the efficacy of NACRT for rectal cancer higher than predicted by serum NOP53 mRNA and FNDC1 mRNA alone, and the differences were statistically significant (Z = 4.645, 4.321, all P < 0.001）. Conclusion The levels of serum NOP53 mRNA and FNDC1 mRNA in patients with locally advanced rectal cancer are increased, which are related to the poor clinicopathological features of patients. Combined with serum NOP53 mRNA, FNDC1 mRNA can effectively predict the clinical efficacy of NACRT in patients with rectal cancer.

参考文献/References:

[1] SIEGEL R L, WAGLE N S, CERCEK A, et al. Colorectal cancer statistics, 2023[J]. CA: A Cancer Journal for Clinicians, 2023,73(3):233-254.
[2] XIONG K, BAO T T, CAO Y B, et al. Efficacy and safety of total neoadjuvant therapy in locally advanced rectal cancer: a meta-analysis[J]. International Journal of Colorectal Disease, 2023,38(1):89.
[3] LIU S, JIANG T, XIAO L, et al. Total neoadjuvant therapy (TNT) versus standard neoadjuvant chemoradiotherapy for locally advanced rectal cancer: a systematic review and meta-analysis[J]. the Oncologist,2021,26(9):1555-1566.
[4] TENG H J, WANG Y, SUI X, et al. Gut microbiotamediated nucleotide synthesis attenuates the response to neoadjuvant chemoradiotherapy in rectal cancer[J]. Cancer Cell, 2023,41(1):124-138,e6.
[5] ATARI N, RAJAN K S, CHIKNE V, et al. Lytic reactivation of the Kaposi’s sarcoma-associated herpesvirus (KSHV) is accompanied by major nucleolar alterations[J]. Viruses, 2022, 14(8):1720.
[6] OROIS A, GARA S K, MORA M, et al. NOP53 as a candidate modifier locus for familial non-medullary thyroid cancer[J]. Genes, 2019,10(11):899.
[7] LIN K, ZHANG L Y, WANG Y S, et al. FNDC1 polymorphism (rs3003174 C > T) increased the incidence of coronary artery aneurysm in patients with Kawasaki disease in a southern Chinese population[J]. Journal of Inflammation Research, 2021,14:2633-2640.
[8] 洪海宁, 朱浩楠, 李超, 等. FNDC1 在肺腺癌中高表达并与不良预后相关[J]. 南方医科大学学报,2022,42(8):1182-1190. HONG H N, ZHU H N, LI C, et al. FNDC1 is highly expressed in lung adenocarcinoma and closely related with poor prognosis[J]. Journal of Southern Medical University, 2022, 42 (8): 1182-1190.
[9] 许瀚, 孟祥瑞, 周悦, 等. FNDC1 蛋白在食管癌组织中的表达及干扰FNDC1 表达对食管癌细胞生物学行为的影响[J]. 郑州大学学报（医学版）,2020,55(4):445-450. XU H, MENG X R, ZHOU Y, et al. Expression of FNDC1 protein expression in esophageal cancer tissue and effect of inhibiting its expression on biological behavior of TE13 and KYSE180 cells[J]. Journal of Zhengzhou University(Medical Sciences), 2020, 55 (4): 445-450.
[10] YU H L, BAI Y P, XIE X Y, et al. RECIST 1.1 versus mRECIST for assessment of tumour response to molecular targeted therapies and disease outcomes in patients with hepatocellular carcinoma: a systematic review and metaanalysis[J]. BMJ Open, 2022,12(6):e052294.
[11] 袁昊雯, 陆思懿, 王皓. 直肠癌新辅助放化疗对肛门功能的影响和治疗进展[J]. 中华肿瘤防治杂志,2022,29(9):681-686. YUAN H W, LU S Y, WANG H. Effect of neoadjuvant chemoradiotherapy on anal function in rectal cancer and its progress in treatment[J]. Chinese Journal of Cancer Prevention and Treatment, 2022, 29 (9): 681-686.
[12] 郑光明, 孙建华, 宋秋月. 结直肠癌组织中锌指蛋白139(ZNF139) 的表达及临床意义研究[J]. 现代检验医学杂志, 2022, 37(4):107-111,168. ZHENG G M, SUN J H, SONG Q Y. Expression and clinical significance of zinc finger protein 139 (ZNF139) in colorectal cancer[J]. Journal of Modern Laboratory Medicine, 2022, 37 (4): 107-111,168.
[13] MIYAO S, SAITO K, OSHIMA R, et al. MTR4 adaptor PICT1 functions in two distinct steps during pre-rRNA processing[J]. Biochemical and Biophysical Research Communications, 2022,637:203-209.
[14] BARELI Y, SHIMON I, TOBAR A, et al. PICT-1 regulates p53 splicing and sensitivity of medullary thyroid carcinoma cells to everolimus[J]. Journal of Neuroendocrinology, 2022, 34(10):e13187.
[15] SHI J, CHEN S Y, SHEN X T, et al. NOP53 undergoes liquid-liquid phase separation and promotes tumor radioresistance[ J]. Cell Death Discovery, 2022,8(1):436.
[16] LI X H, ZHANG N, WU N, et al. Identification of GdRFC1 as a novel regulator of telomerase in Giardia duodenalis[J]. Parasitology Research, 2020, 119(3):1035-1041.
[17] CAMARA-QUILEZ M, BARREIRO-ALONSO A,VIZOSO-VAZQUEZ A, et al. The HMGB1-2 ovarian cancer interactome. The role of HMGB proteins and their interacting partners MIEN1 and NOP53 in ovary cancer and drug-response[J]. Cancers, 2020,12(9):2435.
[18] KACHAEV Z M, IVASHCHENKO S D, KOZLOV E N,et al. Localization and functional roles of components of the translation apparatus in the eukaryotic cell nucleus[J]. Cells,2021, 10(11):3239.
[19] XIAO Y H, WEI R, YUAN Z, et al. Rutin suppresses FNDC1 expression in bone marrow mesenchymal stem cells to inhibit postmenopausal osteoporosis[J]. American Journal of Translational Research,2019,11(10):6680-6690.
[20] CHEN Y W, GAO S S, BEN Z F, et al. The silencing of FNDC1 inhibits the tumorigenesis of breast cancer cells via modulation of the PI3K/Akt signaling pathway[J]. Molecular Medicine Reports, 2021,23(6):479.
[21] WUENSCH T, WIZENTY J, QUINT J, et al. Expression analysis of fibronectin type III domaincontaining (FNDC) genes in inflammatory bowel disease and colorectal cancer[J]. Gastroenterology Research and Practice, 2019, 2019: 3784172.
[22] LU Y, HUANG P P, ZENG X L, et al. Inhibition of FNDC1 suppresses gastric cancer progression by interfering with Gβγ- VEGFR2 complex formation[J]. iScience, 2023,26(9):107534.
[23] CHEN L, LIU J, WANG L F, et al. Up-regulated FNDC1 accelerates stemness and chemoradiation resistance in colorectal cancer cells[J]. Biochemical and Biophysical Research Communications, 2022,602:84-90.
[24] JIANG T, GAO W Y, LIN S J, et al. FNDC1 promotes the invasiveness of gastric cancer via Wnt/β-catenin signaling pathway and correlates with peritoneal metastasis and prognosis[J]. Frontiers in Oncology, 2020,10:590492.
[25] LIU C, LIU L. Hypoxia-related tumor environment correlated with immune infiltration and therapeutic sensitivity in diffuse large B-cell lymphoma[J]. Frontiers in Genetics, 2022,13:1037716.

相似文献/References:

[1]付超英,黄士月,张云霞.直肠癌组织中LncRNA TTN-AS1 及角鲨烯环氧酶表达与临床病理特征及预后相关性研究[J].现代检验医学杂志,2024,39(05):12.[doi:10.3969/j.issn.1671-7414.2024.05.003]
　FU Chaoying,HUANG Shiyue,ZHANG Yunxia.Correlation between the Expression of LncRNA TTN-AS1 and Squalene Epoxidase in Rectal Cancer Tissue and Clinicopathological Characteristics and Prognosis[J].Journal of Modern Laboratory Medicine,2024,39(04):12.[doi:10.3969/j.issn.1671-7414.2024.05.003]

备注/Memo

备注/Memo:
基金项目：陕西省科学技术厅科技计划项目（2021SF-104）。
作者简介：白小慧（1990-），女，硕士研究生，主治医师，研究方向：肿瘤放疗，E-mail：baixiaohui1978@163.com。
通讯作者：赵昌涛（1984-），男，研究方向：肿瘤放疗，E-mail：304317937@qq.com。
更新日期/Last Update: 2025-07-15